Neoadjuvant treatment (i.e treatment before surgery) represents an opportunity to study and monitor “in vivo” treatment-sensitivity of the tumor. It enables leveraging the potential of clinical research in breast cancer and represents per se the optimal framework for translational research. By applying strategies inspired from radiotherapy, immunotherapy, genetics and epigenetics etc… a wide variety of treatments can be evaluated and monitored.
Bilateral breast cancer: the first full study reveals that the tumors are independent of one anotherThis study conducted by Institut Curie, in collaboration with Inserm and the German Breast Cancer Group, is the first to describe bilateral breast cancer with such advanced sequencing technologies. Although the two tumors in each breast have different origins, the type of each tumor (luminal, HER2, triple negative) influences the tumor microenvironment in the other breast, in particular the immune system, and alters the response to treatment.10/03/2023